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Abstract
Pheochromocytomas and paragangliomas are rare neuroendocrine tumors, with 
genetic background in about 40% of cases, involving more than 30 susceptibility 
genes. The susceptibility genes can be divided into three main molecular clusters: 
pseudohypoxic, kinase signaling, and Wnt signaling. Biochemical characteriza-
tion of these particular tumors should be integrated into the diagnostic algorithm 
because it can help apply personalized medicine principles and targeted therapy. 
These tumors can present with very different genotype-phenotype correlations, 
and their characterization can help the clinical practitioner make optimal clinical 
management decisions and prioritize genetic testing. This chapter summarizes the 
most important aspects of genetics and clinical characteristics, together with new 
genotype-phenotype correlation data.
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1. Introduction
Pheochromocytomas (Pheos) and paragangliomas (Pgls) are chromaffin cell-
derived tumors that can develop from the adrenal medulla or the extra-adrenal para-
ganglia. There are two types of Pgls: sympathetic and parasympathetic. Both Pheos 
and sympathetic Pgls are catecholamine-producing tumors. Frequently parasympa-
thetic Pgls are located in the head and neck region, they do not have chromaffin cell 
phenotypic features, and they are in a vast majority of non-secreting tumors [1, 2].
Pheos are rare tumors, with an annual incidence of 2 to 9.1 per 1 million for 
adults patients [3].
The prevalence of Pheos and Pgls in patients with hypertension is between 0.2 
and 0.6% [4].
The early detection of Pheos/Pgls is mandatory because if they go undiag-
nosed and untreated, the cardiovascular morbidity and mortality rates are high. 
Furthermore, the risk of metastatic disease (the presence of metastases in nonchro-
maffin tissue) is increased between 10 and 20% [5, 6].
In the last two decades and especially in the last seven years of medical 
researches, clinical medical studies showed that 40% of these tumors are associ-
ated with underlying germline or somatic mutations in about 30 susceptibility 
genes. Next-Generation Sequencing (NGS) technology has made the sequencing 
of the whole exome routinely available, and many clinical research papers reported 
specific genes associated with Pheos and Pgls [2].
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Catecholamines are produced within chromaffin cells, and their derivatives are 
metabolized within the same cells by an enzyme called catechol-O-methyltrans-
ferase. Norepinephrine and epinephrine are metabolized to normetanephrine and 
metanephrine. Also, dopamine is metabolized to 3-methoxytyramine [7].
Depending on biochemical secretory characteristics, Pheos and sympathetic Pgls 
can be divided into three different biochemical or secretory phenotypes. Pheos and 
sympathetic Pgls with the noradrenergic phenotype secrete especially norepinephrine. 
Besides, Pheos and sympathetic Pgls with the adrenergic phenotype produce epineph-
rine predominantly. Supplementary, Pheos, and sympathetic Pgls, which secrete dopa-
mine, are categorized into a third category named the dopaminergic phenotype [8].
Congruent to The Endocrine Society Clinical Practice Guidelines [4], the clinical 
evaluation of Pheos or Pgls should start with measurements of plasmatic free meta-
nephrines preferentially carried out using blood samples collected in the supine 
position or urinary fractionated metanephrines, altogether with urinary creatinine 
determination. Also, in suspicious dopamine secreting tumors, the plasmatic dosage 
of 3-methoxytyramine is indicated [7].
If the initial biochemical evaluation indicates elevated 3-fold or more above the 
upper cutoffs of catecholamines, the next clinical step should be imaging studies 
to localize the tumor. The preferred initial imaging method is computed tomog-
raphy, followed by magnetic resonance imaging to detect metastatic disease, and 
123I-metaiodobenzylguanidine (MIBG) scintigraphy is recommended [4].
Catecholamine hypersecretion syndrome can induce numerous lethal conditions 
due to the high impact on the cardiovascular system, potentially causing sudden 
deaths. Clinical consequences of catecholamine excess can be myocardial infarc-
tion, cardiac arrhythmias, severe acute hypertension, pulmonary edema, heart 
failure, hypertensive encephalopathy, and cardiogenic shock [9, 10].
In addition to catecholamines’ secretion, Pheos and Pgls could also secrete a 
wide diversity of biomarkers, such as chromogranin A, which can monitor disease 
progression [11, 12]. Subsequently, chromogranin A is released by exocytosis from 
the storage granules and catecholamines into the bloodstream to sympathetic or 
adrenal stimulation. Therefore, chromogranin A level corresponds to the norepi-
nephrine and epinephrine serum levels in the context of Pheos/Pgls [12].
Moreover, chromogranin A levels were reported to be proportional to the tumor 
mass, metastatic disease, especially liver disease, and the presence of the SDHB 
gene mutation [13].
Furthermore, Pheos and Pgls could be responsible in rare situations of ectopic 
secretion syndromes, with mostly cited cases of ectopic ACTH secretion syndrome, 
PTH/PTHrp, and interleukin 6 secretion [14]. However, the majority of ectopic 
secretion is encountered in non-metastatic tumors.
These particular tumors can present with very different genotype-phenotype 
correlations. Depending on the affected gene and its activated intracellular signal-
ing pathways, each tumor is clinically different.
The genetic involvements, together with the good predictive value of histo-
logical PASS -Pheochromocytoma of the Adrenal Gland Scaled Score and GAPP 
algorithms, provide novel prognostic biomarkers and new therapeutic approaches 
for Pheos and Pgls [15].
2. Genetic background
More than 30 genes are currently associated with hereditary Pheos and Pgls, lead-
ing to genetic cause in about 40% of these tumors. Given this high frequency of genetic 
mutations, all patients with Pheos and Pgls should undergo genetic testing [16].
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Genetic screening should be done mostly in patients with a positive family his-
tory, young age at diagnosis, bilateral adrenal Pheos, and metastatic or multifocal 
Pheos/Pgls [4].
NGS technique of targeted gene panels is now the recommended genetic 
screening method in all patients diagnosed with Pheos/Pgls [17].
Depending on the main signaling transduction pathways, these genes have been 
grouped into three clusters: pseudohypoxemia, the tyrosine kinase, and the WNT 
pathways [18].
Gene clusters have different molecular routes to tumorigenesis and provide a 
specific substrate to explore. Furthermore, each cluster is associated with particular 
clinical characteristics and with a specific phenotype.
2.1 Pseudohypoxic cluster
The pseudohypoxic pathway involves the Krebs cycle modulation. It is character-
ized by mutations in genes encoding the endothelial pas domain protein 1/hypoxia-
inducible factor type 2A (EPAS1/HIF2A), von Hippel-Lindau tumor suppressor 
(VHL), succinate dehydrogenase subunits SDHx (SDHA, SDHB, SDHC, SDHD), 
succinate dehydrogenase complex assembly factor 2 (SDHAF2), egl-9 prolyl 
hydroxylase 1 and 2 (EGLN1/2), fumarate hydratase (FH), malate dehydrogenase 
2 (MDH2), prolyl hydroxylase types 1 and 2 (PHD1 and PHD2), and isocitrate 
dehydrogenase (IDH) [19, 20].
Furthermore, the hypoxia/pseudohypoxia cluster is divided into two subgroups. 
The first is associated with germline mutations that affect Krebs cycle and espe-
cially the succinate dehydrogenase subunits (SDHA, SDHB, SDHC, SDHD, and 
SDHAF2), the fumarate hydratase (FH), the malate dehydrogenase 2 (MDH2), 
and isocitrate dehydrogenase (IDH). The second subgroup involves mutation VHL/
EPAS1 genes, with a high rate of angiogenesis and over-expression of vascular 
endothelial-vessel growth factor (VEGF), which increases neo-angiogenesis [3].
Tumors caused by these specific genetic mutations are pseudohypoxic. Hence 
the upregulation of HIF-α is not caused by hypoxia but by other molecular path-
ways. Mutations in genes encoding enzymes lead to the misregulation of cellular 
metabolism, chromatin remodeling, DNA methylation changes, and reactive 
oxygen species production. These specific genetic mutations can induce a metabolic 
alteration that results in an increased dependence on glycolysis, promotion of 
angiogenesis, and succinate, fumarate, and L-malate accumulation. Thus, these 
high concentrations of Krebs cycle metabolites lead to activation of the oncogenetic 
pathway [16, 21].
Furthermore, the hypoxia pathway activation in these types of tumors impli-
cates the glycolytic shift, a typical biochemical feature of these tumors [3].
Tumors in this cluster are more clinically aggressive and are often diagnosed 
with metastatic disease. Also, multiple and multifocal tumors are persistent, and 
the prognostic of patients in this gene’s cluster is most deficient than other suscepti-
bility gene mutations. Moreover, almost all tumors associated with cluster 1 (except 
for VHL- gene) gene mutations are extra-adrenal, and they have the noradrenergic 
phenotype, secreting norepinephrine [22, 23].
2.2 Kinase signaling cluster
Dysregulation of the receptor kinase signaling pathway consists of germline 
or somatic mutations in the RET proto-oncogene (RET), neurofibromin 1 (NF1) 
tumor suppressor, H-RAS and K-RAS proto-oncogenes, transmembrane protein 127 
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(TMEM127), Myc-associated factor X (MAX), chromatin remodeler ATRX, and 
cold shock domain-containing E1 (CSDE1) [24, 25].
Patients with tumors caused by gene mutations in this cluster have an excellent 
general prognosis, except for those with ATRX mutations, where recurrence and 
metastatic disease are more common [26].
Furthermore, Pheos and Pgls from this cluster have a more differentiated cellular 
adrenergic phenotype, they are mostly adrenal tumors, and they rarely develop 
secondary lesions, except for those with ATRX gene mutations [16].
2.3 Wnt signaling cluster
The Wnt pathway plays an essential role in the development, organogenesis and 
is vital for cell survival, migration, and chemotaxis. The Wnt signaling pathway 
is demodulated in different diseases such as cancer, bone diseases, cardiovascular 
diseases, hereditary colorectal cancer, intellectual disability syndrome, neuropsy-
chiatric diseases [3, 27].
Tumors overexpressing genes of the Wnt and Hedgehog pathways consist of the 
Wnt-altered subgroup. These tumors are related to somatic mutations in CSDE1 and 
the mastermind, like transcriptional coactivator 3 (MAML3) [27].
These genotypes display mixed characteristics regarding catecholamine secre-
tion phenotype, involving both noradrenergic and adrenergic phenotype. Moreover, 
Wnt pathway genes are associated with tumors with a high frequency of metastatic 
or recurrent disease [28, 29].
Furthermore, Wnt-altered tumors exhibit high expression of CHGA, a gene 
that encodes chromogranin A, inducing high levels of this biomarker, useful for 
diagnosing and monitoring disease progression [16, 21].
Moreover, somatic mutations in the TERT promoter (SDHx-deficient PPGL) and 
the chromatin modifier KMT2D have also been identified, but they remain validated 
by future researches [23]. However, the somatic mutations in genes associated with 
telomere preservation (inactivation of the ATRX gene or transcriptional activation 
of TERT) are associated with tumors with more aggressive clinical features [23].
3. Biochemical diagnosis and specific secretory phenotypes
Patients with Pheos can present with a complex spectrum of nonspecific 
symptoms, making it challenging for clinical physicians to diagnose correctly.
The biochemical phenotype of the tumor influences the clinical presentation. 
These tumors’ hormonal phenotypes have systemic effects, especially on the cardio-
vascular system and gastrointestinal, ocular, renal systems.
Most patients present with typical clinical signs and symptoms of catechol-
amine excess, including sustained or paroxysmal hypertension episodes, sweating, 
headache, and palpitations. Symptoms may be precipitated due to external factors, 
including a tyramine-rich diet, specific drugs such as histamine, tricyclic antide-
pressants, monoamine oxidase inhibitors, and anesthesia [30, 31]. Moreover, in 10 
to 20% of cases, patients may be entirely asymptomatic, with Pheos/Pgls diagnosed 
as incidentalomas on imaging studies [15].
These clinical characteristics can be grouped into three distinct biochemical 
phenotypes: noradrenergic, adrenergic, and dopaminergic, defined by elevations in 
epinephrine, norepinephrine, and dopamine [23].
Besides, there is a rare subset of Pgls, which are non-secreting tumors, and they 
are referred to as biochemically silent, although elevated levels of chromogranin A 
or specific neuronal enolase can be detected [12].
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Studies reported that tumors with the adrenergic phenotype are more differenti-
ated than the noradrenergic phenotype, which may be more differentiated than the 
dopaminergic phenotype, influencing catecholamine secretion levels [6].
Numerous reports showed a positive correlation between tumor dimensions 
and plasma and urinary concentrations of metanephrines. Moreover, patients with 
metastatic disease have high levels of metanephrines corresponding to the tumor 
burden. Also, chromogranin A levels were associated with tumor mass and meta-
static disease, especially with secondary liver determinations [11, 13].
3.1 The noradrenergic phenotype
The noradrenergic phenotype consists of tumors producing norepinephrine as 
the main secretion pattern. The measurement of plasmatic free normetanephrine 
clinically diagnoses this phenotype. In most cases, these types of tumors are localized 
in extra-adrenal regions, but some medical reports describe them within the adrenal 
glands [23].
Tumors secreting predominantly norepinephrine are associated with a lack of 
signs and symptoms related to catecholamine excess syndrome, and they are more 
frequently clinically silent. Patients can have sustained hypertension due to nor-
epinephrine’s physiological action on the α1 receptors, inducing vasoconstriction. 
Also, the noradrenergic phenotype can have greater intra-operative hemodynamic 
instability compared with patients with adrenergic phenotype [23]. Furthermore, 
α receptor blockage in these patients is the first line of therapy for pre-operative 
patients’ management [32, 33].
Additionally, norepinephrine’s vasoconstrictor effect can cause vasospasms of 
the cerebral, ocular, gastrointestinal, and renal circulation leading to an ischemic 
episode or stroke, optic neuropathy, intestinal necrosis or ischemia, and renal artery 
stenosis, respectively. Moreover, norepinephrine cause reduced intestinal motil-
ity, leading to constipation, paralytic, ileus, and intestinal pseudo-obstruction. 
Furthermore, intestinal circulation vasospasms can also lead to decreased intestinal 
motility with bowel ischemia and gastrointestinal bleeding, increasing the risk of 
developing colonic perforation and abdominal sepsis [34, 35].
Noradrenergic phenotype is suggestive of mutations in cluster 1 category or 
the pseudohypoxic pathway, consisting of the next following genes: succinate 
 dehydrogenase subunits SDHx (SDHA, SDHB, SDHC, SDHD), succinate dehy-
drogenase complex assembly factor 2 (SDHAF2), von Hippel-Lindau tumor 
suppressor (VHL), egl-9 prolyl hydroxylase 1 and 2 (EGLN1/2), malate dehy-
drogenase 2 (MDH2), endothelial pas domain protein 1/hypoxia-inducible factor 
type 2A (EPAS1/HIF2A), fumarate hydratase (FH), and isocitrate dehydrogenase 
(IDH) [6, 25].
3.2 The adrenergic phenotype
Tumors classified as the adrenergic phenotype are characterized by increased 
production and secretion of epinephrine. Epinephrine has numerous physiological 
systemic effects, and it primarily stimulates only β1 and β2 receptors [10].
Patients with Pheos and sympathetic Pgls secreting epinephrine have more 
frequently paroxysmal symptoms of hypertension, palpitations, headache, flush-
ing, and sweating because of their effect on hemodynamics and metabolism [36]. 
Moreover, the adrenergic phenotype catecholamines can be associated with a 
decline in the left ventricular systolic function due to the catecholamine-induced 
myocarditis, also called pheochromocytoma-associated catecholamine cardiomy-
opathy [37, 38].
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These types of tumors are also well-differentiated, and they are frequently 
localized within the adrenal gland. Initially, it was presumed that the increased 
expression of the Phenylethanolamine N-methyltransferase (PNMT) gene is 
involved in the pathophysiology of adrenergic phenotype, but further studies 
stated that the presence of glucocorticoids is not ample enough to induce the 
adrenergic phenotype [20].
Furthermore, adrenergic phenotype tumors are frequently associated 
with adrenal diabetes and dyslipidemia, caused by epinephrine’s metabolic 
effects [39].
Mutations specific to adrenergic phenotype are grouped into cluster 2, caus-
ing activation of kinase signaling pathways. The genes included in cluster 2 are 
RET proto-oncogene (RET) involved in the development of MEN2 syndrome, 
neurofibromin 1 (NF1) tumor suppressor gene involved in neurofibromatosis type 
1, H-RAS and K-RAS proto-oncogenes, transmembrane protein 127 (TMEM127), 
chromatin remodeler (ATRX), Myc-associated factor X (MAX), and cold shock 
domain-containing E1 gene (CSDE1) [31].
Patients presenting with predominantly elevated metanephrines should undergo 
genetic screening for RET and NF1 mutations for the first genetic approach.
All the patients should have pre-operative preparation with α-blockers or other 
medications to control hypertension, arrhythmia, and volume expansion [3].
3.3 The dopaminergic phenotype
The dopaminergic phenotype consists of a sporadic group of neuroendocrine 
tumors that produce and secrete dopamine and its metabolite, 3-methoxytyramine.
Urinary dopamine levels are unreliable markers of this phenotype. Therefore the 
dopaminergic phenotype can be evaluated by plasmatic determination of dopamine 
and 3-methoxytyramine levels [7, 40].
However, Pheos and Pgls associated with SDHx mutations can produce and/or 
secrete dopamine and 3-methoxytyramine.
Tumors of this subgroup are frequently found in extra-adrenal sites and may 
be malignant. Mainly, carotid body tumors, a specific type of head and neck Pgls, 
produce dopamine, which is continuously metabolized into its metabolite [41].
Regarding dopamine’s physiological roles, it is well known that it acts will on D1 
and D2 dopaminergic receptors.
Activation of D1 receptors, located on vascular smooth muscle cells, may lead to 
arterial renal vasodilatation and stimulation of the gastrointestinal tract. Therefore, 
studies reported case reports with patients with chronic diarrhea, nausea, vomiting, 
abdominal pain, weight loss [42].
In contrast, D2 receptors, located in the central nervous system, inhibit norepi-
nephrine secretion, and have a mild negative inotropic effect on the cardiovascular 
system. This mechanism offers a possible explanation for the absence of hyperten-
sion and palpitations in patients with dopaminergic phenotypes [10]. Also, patients 
can have nausea, emesis, and hypotension.
Furthermore, 3-methoxytyramine, the O-methylated dopamine metabolite, is 
a biomarker useful for diagnosing extra-adrenal tumors and multifocal disease [7]. 
Moreover, increased levels are specific to patients with SDHB and SDHD mutations 
and a highly suggestive risk of malignancy [43].
The main characteristics for these tumors and genotype-phenotype correlations 
are summarized in Table 1.
The leading cause of death in patients with Pheos and Pgls is a metastatic 
disease that can occur in about 10–20% of cases [44, 45]. The most cited prognostic 
factors associated with metastasis are extra-adrenal location, a large dimension of 
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the primary tumor germline SDHB mutations, ATRX mutation, and catecholamine 
secretion (noradrenergic or dopaminergic) [6, 16, 46].
4. Peculiarities of pediatric pheochromocytoma
The subgroup of pediatric Pheos and Pgls is still poorly studied, but the latest 
data stated that they have peculiarities compared to the adult population.
Pediatric Pheos and Pgls have a prevalence of 8–9% in recent studies [47], with a 
median age between 12 and 14 years, the youngest age reported to date is four years, 
and a preponderance of boys between 52.7% to 65.5% [48].
In terms of diagnosing algorithms, The European practice guidelines recom-
mend diagnosing Pheos/Pgls plasmatic metanephrines and normetanephrine, 
24-hour urinary fractionated metanephrines, and optionally chromogranin A 
dosing [24].
In the study of [49], the authors reported a high incidence of 70% of genetic 
causes of Pheos/Pgls, with pathogenic mutation, detected preferably with the 
use of NGS.
Considering the clinical spectrum of pediatric Pheos, the prevalence of sus-
tained hypertension is more common in children 70% than adults (50%) [50].
Furthermore, a large majority of 70–80% of pediatric catecholamine secreting 
tumors are functional, making the clinical diagnosis more approachable. Moreover, 
10% of the tumors can be malignant, with about 20% found at multifocal sites 
[50–52]. Subsequently, an increased incidence of extra-adrenal tumors of about 
30% was reported in recent studies [48, 49, 53].
In terms of the genetic landscape of pediatric Pheos, to date, ten genes have been 
described in the medical literature in association with Pheos at a pediatric age: RET, 
VHL, NF1, SDHD, SDHB, SDHA, FH, MAX, HIF2A, and PHD1 [24]. Thus, clini-
cians should always bear in mind the high frequency of the next implicated genes: 
VHL mutations as the most prevalent in pediatric patients ranging from 28.0% to 
49.0% of cases, followed by SDHB and SDHD, RET mutations (1.0–5.4% of cases), 
and NF1 gene mutations (3.0% of cases) [24, 54].
Another important aspect is that about 50% of pediatric Pheos/Pgls can recur, 
compared with the 15–20% proportion reported in the adult population as a 10-year 
probability of recurrence [3]. Subsequently, in the pediatric population, a second-
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5. Conclusions
New data on genetic, metabolic, and biochemical alterations of Pheos and Pgls 
allow us to look for genotype-phenotype correlations.
Depending on biochemical secretory characteristics, Pheos and Pgls can be 
divided into three different biochemical or secretory phenotypes: adrenergic, 
noradrenergic, and dopaminergic.
Depending on the affected gene and its activated intracellular signaling path-
ways, each tumor is clinically different.
Kinase signaling cluster genes are associated with tumors with an adrenergic 
phenotype consisting of epinephrine secretion. These tumors are mostly adrenal 
tumors, and they rarely develop metastatic disease, except for those associated with 
ATRX gene mutations.
Noradrenergic phenotype is suggestive of mutations in the pseudohypoxic 
pathway genes.
The dopaminergic phenotype consists of a sporadic group of neuroendocrine 
tumors that produce and secrete dopamine, and they are associated with SDHx 
mutations.
Regarding pediatric Pheos, the most affected genes are represented by VHL, 
followed by SDHB, SDHD, and NF1. Knowing the high incidence of germline 
mutations in the pediatric population, lifelong monitoring of secondary lesions is 
recommended.
All patients diagnosed with Pheos and Pgls should undergo genetic testing.
Genotype-biochemical phenotype correlations could help in genetic testing 
decision making.
Further studies are necessary for the complete identification of genotype-
specific biochemical markers, which will be important in monitoring disease 
progression and determining treatment strategies. Furthermore, understanding of 
the metabolic and genetic basis of Pheos and Pgls will lead to the development of 
effective forms of therapy for these particular tumors.
© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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